BioCentury | May 7, 2019
Distillery Techniques

Expression of multigene panels in CNS cell types as markers of early AD

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling; tissue markers Gene expression profiling in neurons, oligodendrocytes, microglia and other CNS cell types could help diagnose early Alzheimer's disease. In post-mortem prefrontal cortex samples AD patient and unaffected...
BioCentury | Mar 26, 2019
Distillery Therapeutics

The short-chain fatty acid pentanoate for MS

...of the anti-inflammatory cytokine IL-10 and decreased expression of pro-inflammatory genes, including IL-21 and RAR-related orphan receptor C (RORC...
BioCentury | Feb 15, 2019
Company News

India's Glenmark spinning out innovative assets into U.S. unit

...factor receptor superfamily member 4; PTGES (mPGES-1) - Microsomal prostaglandin E synthase-1; RORγT (RORγ2) - RAR-related orphan receptor C...
BioCentury | Feb 14, 2019
Company News

India's Glenmark spinning out innovative assets into U.S. unit

...factor receptor superfamily member 4; PTGES (mPGES-1) - Microsomal prostaglandin E synthase-1; RORγT (RORγ2) - RAR-related orphan receptor C...
BioCentury | Feb 13, 2019
Distillery Therapeutics

Autoimmune disease

INDICATION: Osteoarthritis Patient sample and mouse studies suggest inhibiting the CH25H-RORA axis could help treat osteoarthritis. In patients, mRNA and protein levels of CH25H and RORA, two factors on the cholesterol metabolism pathway in chondrocytes,...
BioCentury | Nov 13, 2018
Distillery Therapeutics

Hepatic

...inverse agonist TAK-828 in Phase I testing for Crohn’s disease. TARGET/MARKER/PATHWAY: Aryl hydrocarbon receptor (AHR); RAR-related orphan receptor C...
...H. Shoukry, University of Montreal, Montreal, Quebec email: naglaa.shoukry@umontreal.ca Jaime De Leon University of Montreal Aryl hydrocarbon receptor (AHR) RAR-related orphan receptor C...
BioCentury | Aug 29, 2018
Distillery Therapeutics

Inflammation

...asthma, inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD) and various autoimmune diseases. TARGET/MARKER/PATHWAY: RAR-related orphan receptor C...
...Aug. 21, 2018 doi:10.1021/acs.jmedchem.8b00392 CONTACT: Mark E. Schnute, Pfizer Inc., Cambridge, Mass. email: mark.e.schnute@pfizer.com Claire Quang Pfizer Inc. RAR-related orphan receptor C...
BioCentury | Aug 23, 2018
Distillery Therapeutics

Inflammation

...has TAK-828, a RORγT inverse agonist, in Phase I testing to treat Crohn disease. TARGET/MARKER/PATHWAY: RAR-related orphan receptor C...
...anna.vulpetti@novartis.com Contact: Samuel Hintermann, same affiliation as above email: samuel.hintermann@novartis.com Mark Zipkin Novartis AG Novartis Institute for Biomedical Research RAR-related orphan receptor C...
BioCentury | Apr 30, 2018
Company News

Allergan drops RORgammaT inhibitor for psoriasis

...on the company's 1Q18 earnings call. The candidate is an oral small molecule inhibitor of RAR-related orphan receptor C...
...slipped $8.39 to $153.65 on Monday, shedding about $2.7 billion in market cap. Elizabeth S. Eaton VTP-43742 Allergan plc RAR-related orphan receptor C...
BioCentury | Apr 20, 2018
Clinical News

Lycera reports Phase I data for solid tumor candidate LYC-55716

...to treat metastatic NSCLC are also expected by mid-2019. LYC-55716 is an oral selective RAR-related orphan receptor C (RORC...
...and attenuates immunosuppressive mechanisms. Celgene Corp. (NASDAQ:CELG) has an exclusive license to Lycera's portfolio of RORC...
...Ann Arbor, Mich. Product: LYC-55716 Business: Cancer Molecular target: RAR-related orphan receptor C (RORC; RORgamma) Description: Oral selective RORC...
Items per page:
1 - 10 of 90